tirzepatide nutrition guidelines Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from Tirzepatide Meal Plan for Weight

Together, the two studies add to growing evidence that GLP-1 medications may affect biological pathways involved in aging

IGF-1 LR3 is a modified form of insulin-like growth factor 1 designed to stay active in the body longer than natural IGF-1

Weight loss generally improves lipid profiles with decreases in total cholesterol, LDL cholesterol, and triglycerides, and increases in HDL (good) cholesterol

In practice, this means tirzepatide often produces slightly less nausea at equivalent dose escalation points (thanks to the GIP component), potentially stronger appetite suppression once doses reach therapeutic levels, and additional metabolic benefits that semaglutide does not provide

Although the exact mechanisms are not fully understood, this may be due to improved energy regulation

[CrossRef] [Google Scholar] The role of l-carnitine in mitochondria, prevention of metabolic inflexibility and disease initiation